Karoly Toth

List of Publications by Year
in descending order

58 papers	3,170 citations	186265 28 h-index	168389 53 g-index
60 all docs	60 docs citations	60 times ranked	3044 citing authors

#	Article	IF	Citations
1	Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy. Current Gene Therapy, 2014, 13, 421-433.	2.0	411
2	Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature, 1998, 392, 726-730.	27.8	196
3	Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein. Journal of Virology, 2000, 74, 6147-6155.	3.4	190
4	Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Current Opinion in Immunology, 1999, 11, 380-386.	5.5	179
5	miRNA-29b Suppresses Prostate Cancer Metastasis by Regulating Epithelialâ€“Mesenchymal Transition Signaling. Molecular Cancer Therapeutics, 2012, 11, 1166-1173.	4.1	173
6	FUNCTIONS AND MECHANISMS OF ACTION OF THE ADENOVIRUS E3 PROTEINS. International Reviews of Immunology, 2004, 23, 75-111.	3.3	160
7	Syrian Hamster as a Permissive Immunocompetent Animal Model for the Study of Oncolytic Adenovirus Vectors. Cancer Research, 2006, 66, 1270-1276.	0.9	148
8	Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7293-7297.	7.1	124
9	Tissue-Specific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene Therapy. Journal of Virology, 2001, 75, 3314-3324.	3.4	113
10	Overexpression of the ADP (E3-11.6K) Protein Increases Cell Lysis and Spread of Adenovirus. Virology, 2003, 305, 378-387.	2.4	112
11	Immunosuppression Enhances Oncolytic Adenovirus Replication and Antitumor Efficacy in the Syrian Hamster Model. Molecular Therapy, 2008, 16, 1665-1673.	8.2	109
12	Inhibition of TRAIL-Induced Apoptosis and Forced Internalization of TRAIL Receptor 1 by Adenovirus Proteins. Journal of Virology, 2001, 75, 8875-8887.	3.4	104
13	Specific Recruitment of Î³Î´ Regulatory T Cells in Human Breast Cancer. Cancer Research, 2013, 73, 6137-6148.	0.9	94
14	Cotton Rat Tumor Model for the Evaluation of Oncolytic Adenoviruses. Human Gene Therapy, 2005, 16, 139-146.	2.7	62
15	Effect of Preexisting Immunity on Oncolytic Adenovirus Vector INGN 007 Antitumor Efficacy in Immunocompetent and Immunosuppressed Syrian Hamsters. Journal of Virology, 2009, 83, 2130-2139.	3.4	57
16	Syrian Hamster as an Animal Model to Study Oncolytic Adenoviruses and to Evaluate the Efficacy of Antiviral Compounds. Advances in Cancer Research, 2012, 115, 69-92.	5.0	57
17	Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opinion on Biological Therapy, 2010, 10, 353-368.	3.1	54
18	An Oncolytic Adenovirus Vector Combining Enhanced Cell-to-Cell Spreading, Mediated by the ADP Cytolytic Protein, with Selective Replication in Cancer Cells with Deregulated Wnt Signaling. Cancer Research, 2004, 64, 3638-3644.	0.9	53

#	ARTICLE	IF	CITATIONS
19	INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Therapy, 2009, 16, 625-637.	4.6	48
20	New drug on the horizon for treating adenovirus. Expert Opinion on Pharmacotherapy, 2015, 16, 2095-2099.	1.8	46
21	STAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus, Revealing an Important Role of Type I Interferon Response in Viral Control. PLoS Pathogens, 2015, 11, e1005084.	4.7	45
22	An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Therapy, 2009, 16, 644-654.	4.6	42
23	Increasing the Efficacy of Oncolytic Adenovirus Vectors. Viruses, 2010, 2, 1844-1866.	3.3	42
24	Ganciclovir Inhibits Human Adenovirus Replication and Pathogenicity in Permissive Immunosuppressed Syrian Hamsters. Antimicrobial Agents and Chemotherapy, 2014, 58, 7171-7181.	3.2	39
25	Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model. Antiviral Research, 2014, 112, 38-46.	4.1	39
26	Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model. Molecular Therapy, 2009, 17, 1724-1732.	8.2	38
27	Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Therapy, 2003, 10, 193-200.	4.6	37
28	Adenovirus E3-6.7K Protein Is Required in Conjunction with the E3-RID Protein Complex for the Internalization and Degradation of TRAIL Receptor 2. Journal of Virology, 2004, 78, 12297-12307.	3.4	28
29	New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster. Cancer Gene Therapy, 2009, 16, 912-922.	4.6	26
30	Drug development against human adenoviruses and its advancement by Syrian hamster models. FEMS Microbiology Reviews, 2019, 43, 380-388.	8.6	26
31	Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5. Journal of Virology, 2017, 91, .	3.4	24
32	Characterization of an N-Terminal Non-Core Domain of RAG1 Gene Disrupted Syrian Hamster Model Generated by CRISPR Cas9. Viruses, 2018, 10, 243.	3.3	23
33	The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors. Cancer Gene Therapy, 2013, 20, 521-530.	4.6	21
34	Adenovirus replicationâ€“competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc). Cancer Gene Therapy, 2002, 9, 651-654.	4.6	20
35	Valganciclovir Inhibits Human Adenovirus Replication and Pathology in Permissive Immunosuppressed Female and Male Syrian Hamsters. Viruses, 2015, 7, 1409-1428.	3.3	20
36	Transcriptome sequencing and development of an expression microarray platform for liver infection in adenovirus type 5-infected Syrian golden hamsters. Virology, 2015, 485, 305-312.	2.4	20

#	ARTICLE	IF	CITATIONS
37	USC-087 protects Syrian hamsters against lethal challenge with human species C adenoviruses. Antiviral Research, 2018, 153, 1-9.	4.1	19
38	Anti-adenoviral Artificial MicroRNAs Expressed from AAV9 Vectors Inhibit Human Adenovirus Infection in Immunosuppressed Syrian Hamsters. Molecular Therapy - Nucleic Acids, 2017, 8, 300-316.	5.1	18
39	Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters. Cancer Gene Therapy, 2014, 21, 171-178.	4.6	16
40	A multitasking oncolytic adenovirus vector. Molecular Therapy, 2003, 7, 435-437.	8.2	14
41	Syrian Hamster Tumor Model to Study Oncolytic Ad5-Based Vectors. Methods in Molecular Biology, 2012, 797, 53-63.	0.9	14
42	Male Syrian hamsters are more susceptible to intravenous infection with species C human adenoviruses than are females. Virology, 2018, 514, 66-78.	2.4	12
43	Immunocompetent, Semi-Permissive Cotton Rat Tumor Model for the Evaluation of Oncolytic Adenoviruses. , 2007, 130, 157-168.		11
44	The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model. Cancer Gene Therapy, 2013, 20, 531-537.	4.6	11
45	Filociclovir Is a PotentIn VitroandIn VivoInhibitor of Human Adenoviruses. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	11
46	Adenovirus immunoregulatory E3 proteins prolong transplants of human cells in immunocompetent mice. Virus Research, 2005, 108, 149-159.	2.2	10
47	A fully replication-competent adenovirus vector with enhanced oncolytic properties. Cancer Gene Therapy, 2010, 17, 761-770.	4.6	10
48	HAdV-C6 Is a More Relevant Challenge Virus than HAdV-C5 for Testing Antiviral Drugs with the Immunosuppressed Syrian Hamster Model. Viruses, 2017, 9, 147.	3.3	9
49	Generation and characterization of an IL2RG knockout Syrian hamster model for XSCID and HAdV-C6 infection in immunocompromised patients. DMM Disease Models and Mechanisms, 2020, 13, .	2.4	9
50	Construction and Characterization of E1-Minus Replication-Defective Adenovirus Vectors that Express E3 Proteins from the E1 Region. Virology, 2002, 301, 99-108.	2.4	7
51	Combination therapy with brincidofovir and valganciclovir against species C adenovirus infection in the immunosuppressed Syrian hamster model allows for substantial reduction of dose for both compounds. Antiviral Research, 2017, 146, 121-129.	4.1	7
52	HEK? No!. Molecular Therapy, 2002, 5, 654.	8.2	4
53	Adenovirus inhibition of immune-mediated apoptosis. Clinical Immunology Newsletter, 1999, 19, 1-7.	0.1	2
54	642. Toxicological Findings with Oncolytic Adenovirus Vector VRX-007, Wild-Type Ad5, and a Replication-Defective Adenovirus Vector in Syrian Hamsters and C57BL/6 Mice. Molecular Therapy, 2006, 13, S247.	8.2	0

#	Article	IF	Citations
55	651. VRX-007, an Oncolytic Adenovirus Vector, Replicates in Syrian Hamsters but Not Mice: Comparison of Biodistribution Studies Performed in the Syrian Hamster and Mouse. Molecular Therapy, 2006, 13, S251.	8.2	0
56	16. STAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus Type 5, Revealing an Important Role of Type I Interferon Response in Viral Control. Molecular Therapy, 2016, 24, S8.	8.2	0
57	Biographical Feature: William S. M. Wold, Ph.D., 1944-2021. Journal of Virology, 2021, 95, e0118421.	3.4	0
58	Abstract 130: Regulatory role of miR-29b in prostate cancer metastasis. , 2012, , .		0